eBook

Recommendations for Adopting New Approach Methodologies to Reduce Animal Testing in Drug Development

Discover advanced regulatory writing strategies, global regulatory submission best practices, eCTD guidance, ICH M15 updates…

Certara2026 年 7 月 7 日

On-Demand Webinar

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…

Certara2026 年 7 月 1 日

On-Demand Webinar

Building IND-Ready and Investor-Ready Development Programs

Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…

Certara2026 年 6 月 15 日

On-Demand Webinar

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…

Certara2026 年 5 月 26 日

Press Coverage

FDA 在 DOGE 削减资金后重整旗鼓：前监管人员发声

Former FDA officials describe the impact of DOGE-era staffing cuts, lost expertise, and the challenges…

Certara2026 年 5 月 15 日

Guide

如何在药物研发中运用 PBPK 建模与模拟

Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…

Certara2026 年 5 月 12 日

On-Demand Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Learn how to apply FDA NAM guidance to streamline nonclinical development, support IND decisions, and…

Certara2026 年 5 月 8 日

Blog

如何实现药品研发中的动物实验向非动物实验的转型

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

Certara2026 年 5 月 5 日

Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

Certara2026 年 4 月 28 日

Fact Sheet

ToxStudio® Predictive Toxicology Software

Learn about ToxStudio: Predictive toxicology software to support prediction of drug-induced liver injury (DILI), QT…

Certara2026 年 4 月 16 日

New Approach Methodologies (NAMs)

Recommendations for Adopting New Approach Methodologies to Reduce Animal Testing in Drug Development

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Building IND-Ready and Investor-Ready Development Programs

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

FDA 在 DOGE 削减资金后重整旗鼓：前监管人员发声

如何在药物研发中运用 PBPK 建模与模拟

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

如何实现药品研发中的动物实验向非动物实验的转型

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

ToxStudio® Predictive Toxicology Software

订阅时事通讯

快捷链接

解决方案

联系我们